Copyright Reports & Markets. All rights reserved.

Global and United States Mantle Cell Lymphoma Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Mantle Cell Lymphoma Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Acalabrutinib
    • 1.2.3 JCAR-017
    • 1.2.4 JNJ-64052781
    • 1.2.5 Acalisib
    • 1.2.6 IGN-002
    • 1.2.7 IMGN-529
    • 1.2.8 AFM-11
    • 1.2.9 Others
  • 1.3 Market by Application
    • 1.3.1 Global Mantle Cell Lymphoma Treatment Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospital
    • 1.3.3 Clinic
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Mantle Cell Lymphoma Treatment Market Perspective (2015-2026)
  • 2.2 Global Mantle Cell Lymphoma Treatment Growth Trends by Regions
    • 2.2.1 Mantle Cell Lymphoma Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Mantle Cell Lymphoma Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Mantle Cell Lymphoma Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Mantle Cell Lymphoma Treatment Players by Market Size
    • 3.1.1 Global Top Mantle Cell Lymphoma Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Mantle Cell Lymphoma Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global Mantle Cell Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Mantle Cell Lymphoma Treatment Revenue
  • 3.4 Global Mantle Cell Lymphoma Treatment Market Concentration Ratio
    • 3.4.1 Global Mantle Cell Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Mantle Cell Lymphoma Treatment Revenue in 2019
  • 3.5 Key Players Mantle Cell Lymphoma Treatment Area Served
  • 3.6 Key Players Mantle Cell Lymphoma Treatment Product Solution and Service
  • 3.7 Date of Enter into Mantle Cell Lymphoma Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Mantle Cell Lymphoma Treatment Breakdown Data by Type (2015-2026)

  • 4.1 Global Mantle Cell Lymphoma Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Mantle Cell Lymphoma Treatment Forecasted Market Size by Type (2021-2026)

5 Mantle Cell Lymphoma Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Mantle Cell Lymphoma Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global Mantle Cell Lymphoma Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Mantle Cell Lymphoma Treatment Market Size (2015-2026)
  • 6.2 North America Mantle Cell Lymphoma Treatment Market Size by Type (2015-2020)
  • 6.3 North America Mantle Cell Lymphoma Treatment Market Size by Application (2015-2020)
  • 6.4 North America Mantle Cell Lymphoma Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Mantle Cell Lymphoma Treatment Market Size (2015-2026)
  • 7.2 Europe Mantle Cell Lymphoma Treatment Market Size by Type (2015-2020)
  • 7.3 Europe Mantle Cell Lymphoma Treatment Market Size by Application (2015-2020)
  • 7.4 Europe Mantle Cell Lymphoma Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Mantle Cell Lymphoma Treatment Market Size (2015-2026)
  • 8.2 China Mantle Cell Lymphoma Treatment Market Size by Type (2015-2020)
  • 8.3 China Mantle Cell Lymphoma Treatment Market Size by Application (2015-2020)
  • 8.4 China Mantle Cell Lymphoma Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Mantle Cell Lymphoma Treatment Market Size (2015-2026)
  • 9.2 Japan Mantle Cell Lymphoma Treatment Market Size by Type (2015-2020)
  • 9.3 Japan Mantle Cell Lymphoma Treatment Market Size by Application (2015-2020)
  • 9.4 Japan Mantle Cell Lymphoma Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Mantle Cell Lymphoma Treatment Market Size (2015-2026)
  • 10.2 Southeast Asia Mantle Cell Lymphoma Treatment Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Mantle Cell Lymphoma Treatment Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Mantle Cell Lymphoma Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Astex Pharmaceuticals, Inc.
    • 11.1.1 Astex Pharmaceuticals, Inc. Company Details
    • 11.1.2 Astex Pharmaceuticals, Inc. Business Overview
    • 11.1.3 Astex Pharmaceuticals, Inc. Mantle Cell Lymphoma Treatment Introduction
    • 11.1.4 Astex Pharmaceuticals, Inc. Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020))
    • 11.1.5 Astex Pharmaceuticals, Inc. Recent Development
  • 11.2 Bayer AG
    • 11.2.1 Bayer AG Company Details
    • 11.2.2 Bayer AG Business Overview
    • 11.2.3 Bayer AG Mantle Cell Lymphoma Treatment Introduction
    • 11.2.4 Bayer AG Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 11.2.5 Bayer AG Recent Development
  • 11.3 Bristol-Myers Squibb Company
    • 11.3.1 Bristol-Myers Squibb Company Company Details
    • 11.3.2 Bristol-Myers Squibb Company Business Overview
    • 11.3.3 Bristol-Myers Squibb Company Mantle Cell Lymphoma Treatment Introduction
    • 11.3.4 Bristol-Myers Squibb Company Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 11.3.5 Bristol-Myers Squibb Company Recent Development
  • 11.4 Celgene Corporation
    • 11.4.1 Celgene Corporation Company Details
    • 11.4.2 Celgene Corporation Business Overview
    • 11.4.3 Celgene Corporation Mantle Cell Lymphoma Treatment Introduction
    • 11.4.4 Celgene Corporation Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 11.4.5 Celgene Corporation Recent Development
  • 11.5 Cellular Biomedicine Group, Inc.
    • 11.5.1 Cellular Biomedicine Group, Inc. Company Details
    • 11.5.2 Cellular Biomedicine Group, Inc. Business Overview
    • 11.5.3 Cellular Biomedicine Group, Inc. Mantle Cell Lymphoma Treatment Introduction
    • 11.5.4 Cellular Biomedicine Group, Inc. Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 11.5.5 Cellular Biomedicine Group, Inc. Recent Development
  • 11.6 Eisai
    • 11.6.1 Eisai Company Details
    • 11.6.2 Eisai Business Overview
    • 11.6.3 Eisai Mantle Cell Lymphoma Treatment Introduction
    • 11.6.4 Eisai Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 11.6.5 Eisai Recent Development
  • 11.7 EpiZyme, Inc.
    • 11.7.1 EpiZyme, Inc. Company Details
    • 11.7.2 EpiZyme, Inc. Business Overview
    • 11.7.3 EpiZyme, Inc. Mantle Cell Lymphoma Treatment Introduction
    • 11.7.4 EpiZyme, Inc. Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 11.7.5 EpiZyme, Inc. Recent Development
  • 11.8 Fate Therapeutics, Inc.
    • 11.8.1 Fate Therapeutics, Inc. Company Details
    • 11.8.2 Fate Therapeutics, Inc. Business Overview
    • 11.8.3 Fate Therapeutics, Inc. Mantle Cell Lymphoma Treatment Introduction
    • 11.8.4 Fate Therapeutics, Inc. Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 11.8.5 Fate Therapeutics, Inc. Recent Development
  • 11.9 Genentech, Inc.
    • 11.9.1 Genentech, Inc. Company Details
    • 11.9.2 Genentech, Inc. Business Overview
    • 11.9.3 Genentech, Inc. Mantle Cell Lymphoma Treatment Introduction
    • 11.9.4 Genentech, Inc. Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 11.9.5 Genentech, Inc. Recent Development
  • 11.10 Gilead Sciences, Inc.
    • 11.10.1 Gilead Sciences, Inc. Company Details
    • 11.10.2 Gilead Sciences, Inc. Business Overview
    • 11.10.3 Gilead Sciences, Inc. Mantle Cell Lymphoma Treatment Introduction
    • 11.10.4 Gilead Sciences, Inc. Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 11.10.5 Gilead Sciences, Inc. Recent Development
  • 11.11 GlaxoSmithKline Plc
    • 10.11.1 GlaxoSmithKline Plc Company Details
    • 10.11.2 GlaxoSmithKline Plc Business Overview
    • 10.11.3 GlaxoSmithKline Plc Mantle Cell Lymphoma Treatment Introduction
    • 10.11.4 GlaxoSmithKline Plc Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 10.11.5 GlaxoSmithKline Plc Recent Development
  • 11.12 Hutchison MediPharma Limited
    • 10.12.1 Hutchison MediPharma Limited Company Details
    • 10.12.2 Hutchison MediPharma Limited Business Overview
    • 10.12.3 Hutchison MediPharma Limited Mantle Cell Lymphoma Treatment Introduction
    • 10.12.4 Hutchison MediPharma Limited Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 10.12.5 Hutchison MediPharma Limited Recent Development
  • 11.13 ImmunoGen, Inc.
    • 10.13.1 ImmunoGen, Inc. Company Details
    • 10.13.2 ImmunoGen, Inc. Business Overview
    • 10.13.3 ImmunoGen, Inc. Mantle Cell Lymphoma Treatment Introduction
    • 10.13.4 ImmunoGen, Inc. Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 10.13.5 ImmunoGen, Inc. Recent Development
  • 11.14 Immunomedics, Inc.
    • 10.14.1 Immunomedics, Inc. Company Details
    • 10.14.2 Immunomedics, Inc. Business Overview
    • 10.14.3 Immunomedics, Inc. Mantle Cell Lymphoma Treatment Introduction
    • 10.14.4 Immunomedics, Inc. Revenue in Mantle Cell Lymphoma Treatment Business (2015-2020)
    • 10.14.5 Immunomedics, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Mantle Cell Lymphoma Treatment Scope and Market Size
    Mantle Cell Lymphoma Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Mantle Cell Lymphoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Acalabrutinib
    JCAR-017
    JNJ-64052781
    Acalisib
    IGN-002
    IMGN-529
    AFM-11
    Others

    Market segment by Application, split into
    Hospital
    Clinic
    Others

    Based on regional and country-level analysis, the Mantle Cell Lymphoma Treatment market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Mantle Cell Lymphoma Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Astex Pharmaceuticals, Inc.
    Bayer AG
    Bristol-Myers Squibb Company
    Celgene Corporation
    Cellular Biomedicine Group, Inc.
    Eisai
    EpiZyme, Inc.
    Fate Therapeutics, Inc.
    Genentech, Inc.
    Gilead Sciences, Inc.
    GlaxoSmithKline Plc
    Hutchison MediPharma Limited
    ImmunoGen, Inc.
    Immunomedics, Inc.

    Buy now